Tibet Rhodiola Pharmaceutical Holding Co. (SHA:600211)
41.90
+0.45 (1.09%)
Feb 3, 2026, 3:00 PM CST
SHA:600211 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 2,714 | 2,800 | 3,128 | 2,545 | 2,127 | 1,362 |
Other Revenue | 6.73 | 6.73 | 6.24 | 9.69 | 12.06 | 11.49 |
| 2,721 | 2,807 | 3,134 | 2,555 | 2,139 | 1,373 | |
Revenue Growth (YoY) | -7.52% | -10.45% | 22.69% | 19.45% | 55.75% | 9.32% |
Cost of Revenue | 182.68 | 162.1 | 158.67 | 204.74 | 225.8 | 195.69 |
Gross Profit | 2,538 | 2,645 | 2,976 | 2,350 | 1,913 | 1,177 |
Selling, General & Admin | 1,596 | 1,685 | 1,881 | 1,541 | 1,254 | 747.78 |
Research & Development | 40.03 | 28.94 | 17.35 | 88.13 | 60.86 | 7.46 |
Other Operating Expenses | 96.67 | 37.1 | 38.17 | 32.54 | 26.2 | 14.47 |
Operating Expenses | 1,734 | 1,751 | 1,937 | 1,662 | 1,340 | 770.09 |
Operating Income | 804.18 | 893.44 | 1,039 | 688.27 | 572.75 | 407.32 |
Interest Expense | -2.46 | -9.48 | -11.59 | -14.36 | -4.33 | -1.05 |
Interest & Investment Income | 81.79 | 74.38 | 86.22 | 21.35 | 2.67 | 11.43 |
Currency Exchange Gain (Loss) | -2.47 | -2.47 | -0.11 | -3.83 | -4.78 | 3.29 |
Other Non Operating Income (Expenses) | 2.72 | -0.17 | -0.47 | -0.39 | -0.35 | -0.26 |
EBT Excluding Unusual Items | 883.76 | 955.69 | 1,113 | 691.03 | 565.96 | 420.73 |
Gain (Loss) on Sale of Investments | -15.37 | -18.99 | -210.53 | -14.17 | 146.47 | 0.95 |
Gain (Loss) on Sale of Assets | -0.16 | 1.9 | 0.34 | -0.23 | -0.17 | -0.03 |
Asset Writedown | -0.57 | - | -190.38 | -218.62 | -458.06 | - |
Other Unusual Items | 212.05 | 213.48 | 186.03 | 5.36 | 0.64 | 48.66 |
Pretax Income | 1,080 | 1,152 | 898.19 | 463.39 | 254.85 | 470.32 |
Income Tax Expense | 91.88 | 95.01 | 87.95 | 88.08 | 41.82 | 49.65 |
Earnings From Continuing Operations | 987.84 | 1,057 | 810.24 | 375.31 | 213.03 | 420.66 |
Minority Interest in Earnings | -6.64 | -5.79 | -9.33 | -5.47 | -4.09 | -2.57 |
Net Income | 981.2 | 1,051 | 800.91 | 369.84 | 208.94 | 418.1 |
Net Income to Common | 981.2 | 1,051 | 800.91 | 369.84 | 208.94 | 418.1 |
Net Income Growth | 33.05% | 31.26% | 116.56% | 77.01% | -50.03% | 33.87% |
Shares Outstanding (Basic) | 323 | 322 | 323 | 323 | 323 | 322 |
Shares Outstanding (Diluted) | 323 | 322 | 323 | 323 | 323 | 322 |
Shares Change (YoY) | 0.13% | -0.14% | 0.09% | -0.21% | 0.53% | -0.98% |
EPS (Basic) | 3.04 | 3.26 | 2.48 | 1.15 | 0.65 | 1.30 |
EPS (Diluted) | 3.04 | 3.26 | 2.48 | 1.15 | 0.65 | 1.30 |
EPS Growth | 32.88% | 31.45% | 116.37% | 77.38% | -50.29% | 35.19% |
Free Cash Flow | 925.89 | 957.19 | 1,042 | 735.41 | -59.05 | 206.87 |
Free Cash Flow Per Share | 2.87 | 2.97 | 3.23 | 2.28 | -0.18 | 0.64 |
Dividend Per Share | 0.728 | 1.957 | 1.492 | 0.574 | 0.260 | 0.392 |
Dividend Growth | -59.46% | 31.21% | 159.93% | 120.69% | -33.72% | -32.64% |
Gross Margin | 93.28% | 94.23% | 94.94% | 91.98% | 89.44% | 85.75% |
Operating Margin | 29.56% | 31.83% | 33.14% | 26.94% | 26.78% | 29.66% |
Profit Margin | 36.07% | 37.46% | 25.55% | 14.48% | 9.77% | 30.45% |
Free Cash Flow Margin | 34.03% | 34.10% | 33.24% | 28.79% | -2.76% | 15.07% |
EBITDA | 883 | 967.64 | 1,107 | 757.52 | 654.2 | 484.95 |
EBITDA Margin | 32.46% | 34.48% | 35.31% | 29.65% | 30.59% | 35.32% |
D&A For EBITDA | 78.82 | 74.2 | 68.05 | 69.24 | 81.45 | 77.63 |
EBIT | 804.18 | 893.44 | 1,039 | 688.27 | 572.75 | 407.32 |
EBIT Margin | 29.56% | 31.83% | 33.14% | 26.94% | 26.78% | 29.66% |
Effective Tax Rate | 8.51% | 8.25% | 9.79% | 19.01% | 16.41% | 10.56% |
Revenue as Reported | - | - | - | 2,555 | 2,139 | 1,373 |
Advertising Expenses | - | 6.23 | 2.22 | 0.05 | 0.24 | 0.42 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.